{"transactions":[{"id":315,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-02T20:02:28.000Z","date":"2026-08-31","kind":"grant","planned":false,"acquired":true,"shares":21750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders."}],"balance_after":21750,"derivative":{"exercise_price":2.7,"expiration_date":"2036-08-31","underlying":"Common Stock","underlying_shares":21750},"source":{"system":"sec-edgar","filing":"0001413350-26-000009","document":"wk-form4_1788379344.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601485/000141335026000009/wk-form4_1788379344.xml","form_type":"4"}},{"id":730531,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2026-06-22T23:15:02.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":96525,"price":2.25,"value":217181.25,"ownership":{"direct":false,"nature":"The Jay Venkatesan Legacy Trust"},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":5.18,"exercise_date":"2025-04-08","underlying":"Common Stock, $0.0001 par value","underlying_shares":222222},"source":{"system":"sec-edgar","filing":"0001413350-26-000004","document":"wk-form4_1782170099.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000141335026000004/wk-form4_1782170099.xml","form_type":"4"}},{"id":730530,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-22T23:15:02.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":15250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":15250,"derivative":{"exercise_price":1.98,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":15250},"source":{"system":"sec-edgar","filing":"0001413350-26-000004","document":"wk-form4_1782170099.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000141335026000004/wk-form4_1782170099.xml","form_type":"4"}},{"id":730529,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T23:15:02.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":true,"shares":224152,"price":2.25,"value":504342.0,"ownership":{"direct":false,"nature":"The Jay Venkatesan Legacy Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Prefered Stock (\"Series A Preferred\") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 96,525 shares of Series A Preferred that were converted into 222,222 shares of Common Stock and 1,930 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, thereby triggering the automatic conversion of the Series A Preferred into common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The share ownership amount has been adjusted to correct an administrative error in a prior Form 4 filed by the Reporting Person, which inadvertently reported 7,553 shares as direct ownership, rather than indirect ownership."}],"balance_after":231705,"source":{"system":"sec-edgar","filing":"0001413350-26-000004","document":"wk-form4_1782170099.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000141335026000004/wk-form4_1782170099.xml","form_type":"4"}},{"id":730528,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T23:15:02.000Z","date":"2026-05-22","kind":"purchase","planned":false,"acquired":true,"shares":589,"price":1.78,"value":1048.42,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The share ownership amount has been adjusted to correct an administrative error in a prior Form 4 filed by the Reporting Person, which inadvertently reported 7,553 shares as direct ownership, rather than indirect ownership."}],"balance_after":589,"source":{"system":"sec-edgar","filing":"0001413350-26-000004","document":"wk-form4_1782170099.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000141335026000004/wk-form4_1782170099.xml","form_type":"4"}},{"id":803731,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T19:31:50.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":7553,"price":1.94,"value":14652.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of common stock were issued for payment of accrued dividends on the reporting individuals A Convertible Preferred Stock issued on April 8, 2025."}],"balance_after":7553,"source":{"system":"sec-edgar","filing":"0001413350-26-000002","document":"wk-form4_1776799907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000141335026000002/wk-form4_1776799907.xml","form_type":"4"}},{"id":1003754,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-11T00:57:20.000Z","date":"2025-11-07","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":10000,"derivative":{"exercise_price":3.91,"expiration_date":"2035-11-07","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001413350-25-000004","document":"wk-form4_1762822637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000141335025000004/wk-form4_1762822637.xml","form_type":"4"}},{"id":1140330,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-20T20:07:13.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":7900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after\nthe grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after\nthe grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."}],"balance_after":7900,"derivative":{"exercise_price":5.84,"expiration_date":"2035-05-19","underlying":"Common Stock","underlying_shares":7900},"source":{"system":"sec-edgar","filing":"0001601485-25-000088","document":"wk-form4_1747771626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148525000088/wk-form4_1747771626.xml","form_type":"4"}},{"id":1174103,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-04-10T20:03:12.000Z","date":"2025-04-08","kind":"grant","planned":false,"acquired":true,"shares":96525,"price":5.18,"value":499999.5,"ownership":{"direct":false,"nature":"The Jay Venkatesan Legacy Trust"},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date."}],"balance_after":96525,"derivative":{"exercise_price":5.18,"exercise_date":"2025-04-08","underlying":"Common Stock, $0.0001 par value","underlying_shares":96525},"source":{"system":"sec-edgar","filing":"0001708599-25-000038","document":"wk-form4_1744315385.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000038/wk-form4_1744315385.xml","form_type":"4"}},{"id":1269685,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-02-13T22:03:54.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in substantially equal yearly installments beginning on the first anniversary of the grant date such that the stock options shall be fully vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":40000,"derivative":{"exercise_price":4.6,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001708599-25-000021","document":"wk-form4_1739484224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000021/wk-form4_1739484224.xml","form_type":"4"}},{"id":1318525,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2025-01-02T21:05:50.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":4.99,"value":249500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Pre-Funded Warrants do not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"On July 2, 2024, the Reporting Person mistakenly filed a Form 4 reporting the acquisition of an additional 150,000 Common Warrants and 150,000 Pre-Funded Warrants. The Reporting Person is not the beneficial owner of such Common Warrants or Pre-Funded Warrants. As of January 2, 2025, the Reporting Person owned only the Common Warrants and Pre-Funded Warrants reported herein."}],"balance_after":50000,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001601485-25-000002","document":"wk-form4a_1735851944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148525000002/wk-form4a_1735851944.xml","form_type":"4/A","original_submission_date":"2024-07-02"}},{"id":1318524,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants","published_at":"2025-01-02T21:05:50.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Common Warrants expire on July 1, 2029."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"On July 2, 2024, the Reporting Person mistakenly filed a Form 4 reporting the acquisition of an additional 150,000 Common Warrants and 150,000 Pre-Funded Warrants. The Reporting Person is not the beneficial owner of such Common Warrants or Pre-Funded Warrants. As of January 2, 2025, the Reporting Person owned only the Common Warrants and Pre-Funded Warrants reported herein."}],"balance_after":50000,"derivative":{"exercise_price":5,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001601485-25-000002","document":"wk-form4a_1735851944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148525000002/wk-form4a_1735851944.xml","form_type":"4/A","original_submission_date":"2024-07-02"}},{"id":1348338,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2024-11-29T12:39:46.000Z","date":"2024-11-26","kind":"other","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"N/A"}],"balance_after":0,"derivative":{"exercise_price":0.01,"exercise_date":"2024-07-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001601485-24-000105","document":"wk-form4_1732883980.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148524000105/wk-form4_1732883980.xml","form_type":"4"}},{"id":1348337,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-29T12:39:46.000Z","date":"2024-11-26","kind":"other","planned":false,"acquired":true,"shares":50000,"price":0.01,"value":500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 26, 2024, the Reporting Person exercised a pre-funded warrant to purchase an aggregate of 50,000 shares of the Issuer's common stock."}],"balance_after":179581,"source":{"system":"sec-edgar","filing":"0001601485-24-000105","document":"wk-form4_1732883980.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148524000105/wk-form4_1732883980.xml","form_type":"4"}},{"id":1352553,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-25T12:35:21.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":4100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."}],"balance_after":4100,"derivative":{"exercise_price":5.12,"expiration_date":"2034-11-21","underlying":"Common Stock","underlying_shares":4100},"source":{"system":"sec-edgar","filing":"0001601485-24-000095","document":"wk-form4_1732538114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148524000095/wk-form4_1732538114.xml","form_type":"4"}},{"id":1462628,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true}}],"security":"Pre-Funded Warrants","published_at":"2024-07-03T01:53:20.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":4.99,"value":249500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-Funded Warrants do not have an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person may be deemed to have shared voting and investment power over the trust which holds these securities. A Member of the Reporting Person's immediate family is the beneficiary of the trust which holds these securities. The Reporting Person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any."}],"balance_after":50000,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-24-032293","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000114036124032293/form4.xml","form_type":"4"}},{"id":1462627,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true}}],"security":"Common Warrants","published_at":"2024-07-03T01:53:20.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Common Warrants expire on July 1, 2029."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person may be deemed to have shared voting and investment power over the trust which holds these securities. A Member of the Reporting Person's immediate family is the beneficiary of the trust which holds these securities. The Reporting Person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any."}],"balance_after":50000,"derivative":{"exercise_price":5,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-24-032293","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000114036124032293/form4.xml","form_type":"4"}},{"id":1462626,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true}}],"security":"Pre-Funded Warrants","published_at":"2024-07-03T01:53:20.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":4.99,"value":249500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-Funded Warrants do not have an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person may be deemed to have shared voting and investment power over the trust which holds these securities. A Member of the Reporting Person's immediate family is the beneficiary of the trust which holds these securities. The Reporting Person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any."}],"balance_after":50000,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-24-032293","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000114036124032293/form4.xml","form_type":"4"}},{"id":1462625,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true}}],"security":"Common Warrants","published_at":"2024-07-03T01:53:20.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Common Warrants expire on July 1, 2029."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person may be deemed to have shared voting and investment power over the trust which holds these securities. A Member of the Reporting Person's immediate family is the beneficiary of the trust which holds these securities. The Reporting Person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any."}],"balance_after":50000,"derivative":{"exercise_price":5,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-24-032293","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000114036124032293/form4.xml","form_type":"4"}},{"id":1462624,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true}}],"security":"Pre-Funded Warrants","published_at":"2024-07-03T01:53:20.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":4.99,"value":249500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-Funded Warrants do not have an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person may be deemed to have shared voting and investment power over the trust which holds these securities. A Member of the Reporting Person's immediate family is the beneficiary of the trust which holds these securities. The Reporting Person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any."}],"balance_after":50000,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-24-032293","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000114036124032293/form4.xml","form_type":"4"}},{"id":1462623,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true}}],"security":"Common Warrants","published_at":"2024-07-03T01:53:20.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Common Warrants expire on July 1, 2029."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person may be deemed to have shared voting and investment power over the trust which holds these securities. A Member of the Reporting Person's immediate family is the beneficiary of the trust which holds these securities. The Reporting Person disclaims beneficial ownership of the securities held by the trust which holds these securities except to the extent of his pecuniary interest therein, if any."}],"balance_after":50000,"derivative":{"exercise_price":5,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-24-032293","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000114036124032293/form4.xml","form_type":"4"}},{"id":1462622,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true}}],"security":"Pre-Funded Warrants","published_at":"2024-07-03T01:53:20.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":4.99,"value":249500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Pre-Funded Warrants do not have an expiration date."}],"balance_after":50000,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-24-032293","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000114036124032293/form4.xml","form_type":"4"}},{"id":1462621,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true}}],"security":"Common Warrants","published_at":"2024-07-03T01:53:20.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Common Warrants expire on July 1, 2029."}],"balance_after":50000,"derivative":{"exercise_price":5,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-24-032293","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000114036124032293/form4.xml","form_type":"4"}},{"id":1697865,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-12-29T22:05:40.000Z","date":"2023-12-28","kind":"grant","planned":false,"acquired":true,"shares":4100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."}],"balance_after":4100,"derivative":{"exercise_price":8.26,"expiration_date":"2033-12-28","underlying":"Common Stock","underlying_shares":4100},"source":{"system":"sec-edgar","filing":"0001140361-23-060235","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000114036123060235/form4.xml","form_type":"4"}},{"id":2205220,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-07-19T20:38:14.000Z","date":"2022-07-15","kind":"exercise","acquired":false,"shares":20063,"price":0.45,"value":9028.35,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\"). Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Reporting Person was initially granted an option to acquire 300,000 shares, 75,000 shares of which vested on May 25, 2016, and the remaining shares vested or vest in 36 substantially equal monthly installments starting on September 1, 2016, subject to the Reporting person's continued service with the Issuer and certain change of control provisions."}],"balance_after":70000,"derivative":{"exercise_price":0.45,"expiration_date":"2025-12-15","underlying":"Common Stock","underlying_shares":20063},"source":{"system":"sec-edgar","filing":"0001626199-22-000052","document":"wf-form4_165826307798060.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000162619922000052/wf-form4_165826307798060.xml","form_type":"4"}},{"id":2205219,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-19T20:38:14.000Z","date":"2022-07-15","kind":"exercise","acquired":true,"shares":20063,"price":0.45,"value":9028.35,"ownership":{"direct":true},"balance_after":238126,"source":{"system":"sec-edgar","filing":"0001626199-22-000052","document":"wf-form4_165826307798060.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000162619922000052/wf-form4_165826307798060.xml","form_type":"4"}},{"id":2253209,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Warrant to Purchase Common Stock","published_at":"2022-05-27T20:20:09.000Z","date":"2021-02-09","kind":"other","acquired":false,"shares":396329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 396,329 shares of the Issuer's common stock for $6.43 a share. The Reporting Person paid the exercise price on a cashless basis, resulting in the issuer's withholding of 159,177 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 237,152 shares of common stock."}],"balance_after":0,"derivative":{"exercise_price":6.43,"expiration_date":"2028-07-05","underlying":"Common Stock","underlying_shares":396329},"source":{"system":"sec-edgar","filing":"0001601485-22-000045","document":"wf-form4a_165368278065712.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148522000045/wf-form4a_165368278065712.xml","form_type":"4/A","original_submission_date":"2021-02-11"}},{"id":2253208,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-05-27T20:20:09.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":262,"price":11.57,"value":3031.34,"ownership":{"direct":true},"balance_after":1439525,"source":{"system":"sec-edgar","filing":"0001601485-22-000045","document":"wf-form4a_165368278065712.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148522000045/wf-form4a_165368278065712.xml","form_type":"4/A","original_submission_date":"2021-02-11"}},{"id":2253207,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-05-27T20:20:09.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":159177,"price":16,"value":2546832.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 396,329 shares of the Issuer's common stock for $6.43 a share. The Reporting Person paid the exercise price on a cashless basis, resulting in the issuer's withholding of 159,177 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 237,152 shares of common stock."}],"balance_after":1367263,"source":{"system":"sec-edgar","filing":"0001601485-22-000045","document":"wf-form4a_165368278065712.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148522000045/wf-form4a_165368278065712.xml","form_type":"4/A","original_submission_date":"2021-02-11"}},{"id":2253206,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-05-27T20:20:09.000Z","date":"2021-02-09","kind":"other","acquired":true,"shares":396329,"price":6.43,"value":2548395.47,"ownership":{"direct":true},"balance_after":1598440,"source":{"system":"sec-edgar","filing":"0001601485-22-000045","document":"wf-form4a_165368278065712.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148522000045/wf-form4a_165368278065712.xml","form_type":"4/A","original_submission_date":"2021-02-11"}},{"id":2253205,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-05-27T20:18:25.000Z","date":"2022-05-25","kind":"purchase","acquired":true,"shares":11313,"price":1.2466,"value":14102.7858,"ownership":{"direct":true},"balance_after":1891947,"source":{"system":"sec-edgar","filing":"0001601485-22-000043","document":"wf-form4_165368268236817.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148522000043/wf-form4_165368268236817.xml","form_type":"4"}},{"id":2256581,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-05-25T21:58:29.000Z","date":"2022-05-24","kind":"purchase","acquired":true,"shares":32200,"price":1.24,"value":39928.0,"ownership":{"direct":true},"balance_after":1721457,"source":{"system":"sec-edgar","filing":"0001601485-22-000039","document":"wf-form4_165351588830337.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148522000039/wf-form4_165351588830337.xml","form_type":"4"}},{"id":2256580,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-05-25T21:58:29.000Z","date":"2022-05-20","kind":"purchase","acquired":true,"shares":50000,"price":1.23,"value":61500.0,"ownership":{"direct":true},"balance_after":1689257,"source":{"system":"sec-edgar","filing":"0001601485-22-000039","document":"wf-form4_165351588830337.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148522000039/wf-form4_165351588830337.xml","form_type":"4"}},{"id":2350066,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-04T21:22:42.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The total number of options vest in equal parts on July 31, 2022 and December 31, 2022, such that 100% of the options will be fully vested and exercisable on December 31, 2022."}],"balance_after":760000,"derivative":{"exercise_price":1.94,"expiration_date":"2032-03-02","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001601485-22-000014","document":"wf-form4_164642894442998.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148522000014/wf-form4_164642894442998.xml","form_type":"4"}},{"id":2350065,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-04T21:22:42.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The total number of options vest in forty-eight (48) successive and equal monthly installments as measured from March 3, 2022 (the \"Vesting Commencement Date\"), such that 100% of the options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":600000,"derivative":{"exercise_price":1.94,"expiration_date":"2032-03-02","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001601485-22-000014","document":"wf-form4_164642894442998.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148522000014/wf-form4_164642894442998.xml","form_type":"4"}},{"id":2448554,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-01-04T22:37:02.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 3, 2022 and 1/12th of the shares subject to the option shall vest monthly thereafter."}],"balance_after":10000,"derivative":{"exercise_price":13.89,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-22-000016","document":"wf-form4_164133579169890.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000162619922000016/wf-form4_164133579169890.xml","form_type":"4"}},{"id":2456996,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-12-29T21:08:05.000Z","date":"2021-12-28","kind":"purchase","acquired":true,"shares":210337,"price":2.6617,"value":559853.9929,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.55 to $2.75 inclusive."}],"balance_after":1639257,"source":{"system":"sec-edgar","filing":"0001601485-21-000095","document":"wf-form4_164081206871822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148521000095/wf-form4_164081206871822.xml","form_type":"4"}},{"id":2456995,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-12-29T21:08:05.000Z","date":"2021-12-27","kind":"purchase","acquired":true,"shares":66907,"price":2.5486,"value":170519.1802,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.54 to $2.55 inclusive."}],"balance_after":1428920,"source":{"system":"sec-edgar","filing":"0001601485-21-000095","document":"wf-form4_164081206871822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148521000095/wf-form4_164081206871822.xml","form_type":"4"}},{"id":2460804,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-12-22T21:06:45.000Z","date":"2021-12-20","kind":"purchase","acquired":true,"shares":3527,"price":2.5449,"value":8975.8623,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.52 to $2.55 inclusive."}],"balance_after":1362013,"source":{"system":"sec-edgar","filing":"0001601485-21-000093","document":"wf-form4_164020718382276.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148521000093/wf-form4_164020718382276.xml","form_type":"4"}},{"id":2463719,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-12-20T23:44:28.000Z","date":"2021-12-17","kind":"purchase","acquired":true,"shares":13742,"price":2.5439,"value":34958.2738,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.55 inclusive."}],"balance_after":1358486,"source":{"system":"sec-edgar","filing":"0001601485-21-000089","document":"wf-form4_164004385539278.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148521000089/wf-form4_164004385539278.xml","form_type":"4"}},{"id":2463718,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-12-20T23:44:28.000Z","date":"2021-12-16","kind":"purchase","acquired":true,"shares":27883,"price":2.5461,"value":70992.9063,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.55 inclusive."}],"balance_after":1344744,"source":{"system":"sec-edgar","filing":"0001601485-21-000089","document":"wf-form4_164004385539278.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148521000089/wf-form4_164004385539278.xml","form_type":"4"}},{"id":2465791,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-12-17T22:13:23.000Z","date":"2021-12-15","kind":"purchase","acquired":true,"shares":77604,"price":2.4091,"value":186955.7964,"ownership":{"direct":true},"balance_after":1316861,"source":{"system":"sec-edgar","filing":"0001601485-21-000087","document":"wf-form4_163977918794672.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148521000087/wf-form4_163977918794672.xml","form_type":"4"}},{"id":2465790,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-12-17T22:13:23.000Z","date":"2021-06-24","kind":"tax_withholding","acquired":false,"shares":41091,"price":13.78,"value":566233.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were withheld to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\")."}],"balance_after":1239257,"source":{"system":"sec-edgar","filing":"0001601485-21-000087","document":"wf-form4_163977918794672.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000160148521000087/wf-form4_163977918794672.xml","form_type":"4"}},{"id":2563008,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-21T21:14:16.000Z","date":"2021-09-17","kind":"sale","acquired":false,"shares":400000,"price":9.4,"value":3760000.0,"ownership":{"direct":false,"nature":"By Alpine ImmunoSciences, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were sold in a private transaction to an investor in the Issuer simultaneously with the closing of the Issuer's private placement on September 17, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P.  Dr. Venkatesan is a Managing Partner of Alpine BioVenture GP, LLC.  Dr. Venkatesan is also a limited partner of Alpine ImmunoSciences, L.P.  By virtue of such relationships, Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."}],"balance_after":2600980,"source":{"system":"sec-edgar","filing":"0001626199-21-000113","document":"wf-form4_163225883908242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000162619921000113/wf-form4_163225883908242.xml","form_type":"4"}},{"id":2740748,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-04-23T22:14:07.000Z","date":"2021-03-31","kind":"exercise","acquired":false,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option became fully vested and exercisable on January 2, 2021."}],"balance_after":0,"derivative":{"exercise_price":3.6233,"expiration_date":"2030-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-21-000044","document":"wf-form4_161921602524556.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000162619921000044/wf-form4_161921602524556.xml","form_type":"4"}},{"id":2740747,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-04-23T22:14:07.000Z","date":"2021-03-30","kind":"exercise","acquired":false,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option became fully vested and exercisable on January 2, 2020."}],"balance_after":0,"derivative":{"exercise_price":4.09,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-21-000044","document":"wf-form4_161921602524556.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000162619921000044/wf-form4_161921602524556.xml","form_type":"4"}},{"id":2740746,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-23T22:14:07.000Z","date":"2021-03-31","kind":"exercise","acquired":true,"shares":7650,"price":3.6233,"value":27718.245,"ownership":{"direct":true},"balance_after":218063,"source":{"system":"sec-edgar","filing":"0001626199-21-000044","document":"wf-form4_161921602524556.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000162619921000044/wf-form4_161921602524556.xml","form_type":"4"}},{"id":2740745,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-23T22:14:07.000Z","date":"2021-03-30","kind":"exercise","acquired":true,"shares":7650,"price":4.09,"value":31288.5,"ownership":{"direct":true},"balance_after":210413,"source":{"system":"sec-edgar","filing":"0001626199-21-000044","document":"wf-form4_161921602524556.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000162619921000044/wf-form4_161921602524556.xml","form_type":"4"}},{"id":2866416,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Convertible Promissory Note","published_at":"2021-02-12T00:25:44.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"price":0,"reported_value":3138.9,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The convertible promissory note converted immediately prior to the consummation of the IPO into Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The convertible promissory note (\"Convertible Note\") had a maturity date of August 14, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $18.00 per Common Share."}],"balance_after":0,"derivative":{"exercise_price":16,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001567619-21-003193","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000156761921003193/doc1.xml","form_type":"4"}},{"id":2866415,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Warrant to Purchase Common Stock","published_at":"2021-02-12T00:25:44.000Z","date":"2021-02-09","kind":"other","acquired":false,"shares":237152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 396,328 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's IPO price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's IPO, the Issuer withheld 159,177 of the warrant shares to pay the exercise price and issued the remaining 237,152 shares of common stock to Reporting Person."}],"balance_after":0,"derivative":{"exercise_price":6.43,"expiration_date":"2028-07-05","underlying":"Common Stock","underlying_shares":237152},"source":{"system":"sec-edgar","filing":"0001567619-21-003193","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000156761921003193/doc1.xml","form_type":"4"}},{"id":2866414,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Series C Cumulative Convertible Preferred","published_at":"2021-02-12T00:25:44.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":1804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 91.52 shares of the issuer's Common Stock immediately prior to the consummation of the issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 91.52 shares of the issuer's Common Stock immediately prior to the consummation of the issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 91.52 shares of the issuer's Common Stock immediately prior to the consummation of the issuer's IPO and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1804},"source":{"system":"sec-edgar","filing":"0001567619-21-003193","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000156761921003193/doc1.xml","form_type":"4"}},{"id":2866413,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-02-12T00:25:44.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":262,"price":11.57,"value":3031.34,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 246,299 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":1280348,"source":{"system":"sec-edgar","filing":"0001567619-21-003193","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000156761921003193/doc1.xml","form_type":"4"}},{"id":2866412,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-02-12T00:25:44.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":159177,"price":16,"value":2546832.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 246,299 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 396,328 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's IPO price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's IPO, the Issuer withheld 159,177 of the warrant shares to pay the exercise price and issued the remaining 237,152 shares of common stock to Reporting Person."}],"balance_after":1208086,"source":{"system":"sec-edgar","filing":"0001567619-21-003193","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000156761921003193/doc1.xml","form_type":"4"}},{"id":2866411,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-02-12T00:25:44.000Z","date":"2021-02-09","kind":"other","acquired":true,"shares":237152,"price":6.43,"value":1524887.36,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 246,299 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 396,328 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's IPO price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's IPO, the Issuer withheld 159,177 of the warrant shares to pay the exercise price and issued the remaining 237,152 shares of common stock to Reporting Person."}],"balance_after":1439263,"source":{"system":"sec-edgar","filing":"0001567619-21-003193","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000156761921003193/doc1.xml","form_type":"4"}},{"id":2866410,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-02-12T00:25:44.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":165094,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 91.52 shares of the issuer's Common Stock immediately prior to the consummation of the issuer's IPO and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 246,299 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":1202111,"source":{"system":"sec-edgar","filing":"0001567619-21-003193","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000156761921003193/doc1.xml","form_type":"4"}},{"id":2866409,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-02-12T00:25:44.000Z","date":"2021-02-09","kind":"tax_withholding","acquired":false,"shares":31966,"price":16,"value":511456.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were withheld to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 246,299 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":1037017,"source":{"system":"sec-edgar","filing":"0001567619-21-003193","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000156761921003193/doc1.xml","form_type":"4"}},{"id":2874354,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-08T17:57:48.000Z","date":"2021-02-04","kind":"grant","acquired":true,"shares":178920,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from  February 4, 2021 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":178920,"derivative":{"exercise_price":16,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":178920},"source":{"system":"sec-edgar","filing":"0001567619-21-002411","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000156761921002411/doc1.xml","form_type":"4"}},{"id":4612917,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-01-06T00:03:36.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 4, 2021 and 1/12th of the shares subject to the option shall vest monthly thereafter."}],"balance_after":7650,"derivative":{"exercise_price":13.45,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-21-000019","document":"wf-form4_160989139272459.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000162619921000019/wf-form4_160989139272459.xml","form_type":"4"}},{"id":2934482,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-22T22:30:09.000Z","date":"2020-12-22","kind":"other","acquired":true,"shares":181024,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Acquisition by the Reporting Person pursuant to the Distribution."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Acquisition by the Reporting Person pursuant to the Distribution."}],"balance_after":202763,"source":{"system":"sec-edgar","filing":"0000899243-20-034852","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924320034852/doc4.xml","form_type":"4"}},{"id":2934481,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-22T22:30:09.000Z","date":"2020-12-22","kind":"other","acquired":false,"shares":993801,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Alpine ImmunoSciences, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Alpine ImmunoSciences, L.P. distributed these shares to its limited partners on a pro rata basis for no consideration (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Alpine ImmunoSciences, L.P. distributed these shares to its limited partners on a pro rata basis for no consideration (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P.  Dr. Venkatesan is a Managing Partner of Alpine BioVenture GP, LLC.  Dr. Venkatesan is also a limited partner of Alpine ImmunoSciences, L.P.  By virtue of such relationships, Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3000980,"source":{"system":"sec-edgar","filing":"0000899243-20-034852","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924320034852/doc4.xml","form_type":"4"}},{"id":3086307,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-08T20:46:43.000Z","date":"2020-07-06","kind":"exercise","acquired":false,"shares":12930,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option vested in 48 substantially equal monthly installments from February 20, 2015, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."}],"balance_after":0,"derivative":{"exercise_price":1.03,"expiration_date":"2025-04-28","underlying":"Common Stock","underlying_shares":12930},"source":{"system":"sec-edgar","filing":"0001209191-20-041770","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000120919120041770/doc4.xml","form_type":"4"}},{"id":3086306,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-08T20:46:43.000Z","date":"2020-07-06","kind":"exercise","acquired":false,"shares":9310,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vested 25% on October 1, 2014, and the remaining 75% vested in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."}],"balance_after":0,"derivative":{"exercise_price":0.65,"expiration_date":"2024-02-17","underlying":"Common Stock","underlying_shares":9310},"source":{"system":"sec-edgar","filing":"0001209191-20-041770","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000120919120041770/doc4.xml","form_type":"4"}},{"id":3086305,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-08T20:46:43.000Z","date":"2020-07-06","kind":"exercise","acquired":true,"shares":12930,"price":1.03,"value":13317.9,"ownership":{"direct":true},"balance_after":324473,"source":{"system":"sec-edgar","filing":"0001209191-20-041770","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000120919120041770/doc4.xml","form_type":"4"}},{"id":3086304,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-08T20:46:43.000Z","date":"2020-07-06","kind":"exercise","acquired":true,"shares":9310,"price":0.65,"value":6051.5,"ownership":{"direct":true},"balance_after":311544,"source":{"system":"sec-edgar","filing":"0001209191-20-041770","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000120919120041770/doc4.xml","form_type":"4"}},{"id":3118537,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-08T23:22:58.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":21693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of June 4, 2020, provided the Reporting Person remains in continuous service on each vesting date."}],"balance_after":21693,"derivative":{"exercise_price":2.79,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":21693},"source":{"system":"sec-edgar","filing":"0001209191-20-035126","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000120919120035126/doc4.xml","form_type":"4"}},{"id":3318183,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-01-07T01:02:08.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 2, 2020 and 1/12th of the shares subject to the option shall vest monthly thereafter."}],"balance_after":7650,"derivative":{"exercise_price":3.6233,"expiration_date":"2030-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0000899243-20-000641","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924320000641/doc4.xml","form_type":"4"}},{"id":3445520,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-06T21:11:20.000Z","date":"2019-08-02","kind":"purchase","acquired":true,"shares":250000,"price":2,"value":500000.0,"ownership":{"direct":true},"balance_after":302234,"source":{"system":"sec-edgar","filing":"0001698530-19-000111","document":"wf-form4_156512586376371.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000169853019000111/wf-form4_156512586376371.xml","form_type":"4"}},{"id":3489441,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T21:37:38.000Z","date":"2019-06-14","kind":"grant","acquired":true,"shares":21693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in 12 substantially equal monthly installments from June 14, 2019,  provided that the option will vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service with the Issuer through each such date or, if earlier, such annual meeting and certain change of control provisions."}],"balance_after":21693,"derivative":{"exercise_price":2.78,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":21693},"source":{"system":"sec-edgar","filing":"0001698530-19-000065","document":"wf-form4_156054824434724.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000169853019000065/wf-form4_156054824434724.xml","form_type":"4"}},{"id":3690567,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2019-01-23T01:44:37.000Z","date":"2019-01-18","kind":"purchase","acquired":true,"shares":74441,"ownership":{"direct":false,"nature":"Alpine ImmunoSciences, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired in a private placement pursuant to that Securities Purchase Agreement, dated as of January 15, 2019, by and among the Issuer and the Purchasers set forth on the signature pages thereto (the \"Securities Purchase Agreement\"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired in a private placement pursuant to that Securities Purchase Agreement, dated as of January 15, 2019, by and among the Issuer and the Purchasers set forth on the signature pages thereto (the \"Securities Purchase Agreement\"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Venkatesan is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Venkatesan is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Venkatesan is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Venkatesan is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":74441,"derivative":{"exercise_price":12.74,"exercise_date":"2019-01-18","expiration_date":"2024-01-18","underlying":"Common Stock","underlying_shares":74441},"source":{"system":"sec-edgar","filing":"0000899243-19-001661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924319001661/doc4.xml","form_type":"4"}},{"id":3690566,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-23T01:44:37.000Z","date":"2019-01-18","kind":"purchase","acquired":true,"shares":190875,"price":5.37,"value":1024998.75,"ownership":{"direct":false,"nature":"Alpine ImmunoSciences, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired in a private placement pursuant to that Securities Purchase Agreement, dated as of January 15, 2019, by and among the Issuer and the Purchasers set forth on the signature pages thereto (the \"Securities Purchase Agreement\"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares acquired in a private placement pursuant to that Securities Purchase Agreement, dated as of January 15, 2019, by and among the Issuer and the Purchasers set forth on the signature pages thereto (the \"Securities Purchase Agreement\"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Venkatesan is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Venkatesan is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Venkatesan is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Venkatesan is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3994781,"source":{"system":"sec-edgar","filing":"0000899243-19-001661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924319001661/doc4.xml","form_type":"4"}},{"id":3703785,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2019-01-04T21:01:33.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 2, 2019 and 1/12th of the shares subject to the option shall vest monthly thereafter."}],"balance_after":7650,"derivative":{"exercise_price":4.09,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0000899243-19-000499","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924319000499/doc4.xml","form_type":"4"}},{"id":3885998,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-21T22:14:47.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":21693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in 12 substantially equal monthly installments from June 19, 2018, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."}],"balance_after":21693,"derivative":{"exercise_price":5.82,"expiration_date":"2028-06-18","underlying":"Common Stock","underlying_shares":21693},"source":{"system":"sec-edgar","filing":"0001698530-18-000036","document":"wf-form4_152961927100358.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000169853018000036/wf-form4_152961927100358.xml","form_type":"4"}},{"id":4107316,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to buy)","published_at":"2018-01-04T22:18:43.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option become vested and exercisable on January 2, 2019 and 1/36th of the remaining shares subject to the option shall vest monthly thereafter."}],"balance_after":25000,"derivative":{"exercise_price":11.31,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-000490","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924318000490/doc4.xml","form_type":"4"}},{"id":4199934,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-09-29T01:40:29.000Z","date":"2017-09-26","kind":"grant","acquired":true,"shares":24824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"shares","element":"transactionShares","label":"F5","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option vests in 12 substantially equal monthly installments from January 4, 2017, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."}],"balance_after":24824,"derivative":{"exercise_price":4.21,"expiration_date":"2027-01-04","underlying":"Common Stock","underlying_shares":24824},"source":{"system":"sec-edgar","filing":"0000899243-17-022826","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924317022826/doc4.xml","form_type":"4"}},{"id":4199933,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-09-29T01:40:29.000Z","date":"2017-09-26","kind":"grant","acquired":true,"shares":12929,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"shares","element":"transactionShares","label":"F5","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option vests in 48 substantially equal monthly installments from February 20, 2015, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."}],"balance_after":12929,"derivative":{"exercise_price":1.03,"expiration_date":"2025-04-28","underlying":"Common Stock","underlying_shares":12929},"source":{"system":"sec-edgar","filing":"0000899243-17-022826","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924317022826/doc4.xml","form_type":"4"}},{"id":4199932,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-09-29T01:40:29.000Z","date":"2017-09-26","kind":"grant","acquired":true,"shares":9309,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"shares","element":"transactionShares","label":"F5","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option vested 25% on October 1, 2014, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."}],"balance_after":9309,"derivative":{"exercise_price":0.65,"expiration_date":"2024-02-17","underlying":"Common Stock","underlying_shares":9309},"source":{"system":"sec-edgar","filing":"0000899243-17-022826","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924317022826/doc4.xml","form_type":"4"}},{"id":4199931,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-29T01:40:29.000Z","date":"2017-09-26","kind":"purchase","acquired":true,"shares":66666,"price":3,"value":199998.0,"ownership":{"direct":false,"nature":"By Ayer Special Situations Fund I, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is the managing director of the Ayer Special Situations Fund I, LP (\"Ayer Fund\") and has voting or dispositive power over the shares held by the Ayer Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":156858,"source":{"system":"sec-edgar","filing":"0000899243-17-022826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924317022826/doc4.xml","form_type":"4"}},{"id":4199930,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-29T01:40:29.000Z","date":"2017-09-26","kind":"grant","acquired":true,"shares":52234,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."}],"balance_after":52234,"source":{"system":"sec-edgar","filing":"0000899243-17-022826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924317022826/doc4.xml","form_type":"4"}},{"id":4199929,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-29T01:40:29.000Z","date":"2017-09-26","kind":"other","acquired":true,"shares":90192,"ownership":{"direct":false,"nature":"By Ayer Special Situations Fund I, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is the managing director of the Ayer Special Situations Fund I, LP (\"Ayer Fund\") and has voting or dispositive power over the shares held by the Ayer Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":90192,"source":{"system":"sec-edgar","filing":"0000899243-17-022826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924317022826/doc4.xml","form_type":"4"}},{"id":4199928,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-29T01:40:29.000Z","date":"2017-09-26","kind":"other","acquired":true,"shares":190957,"ownership":{"direct":false,"nature":"By The Venkatesan-Louizides Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is the trustee of the Venkatesan-Louizides Trust (the \"Trust\") and has voting or dispositive power over the shares held by the Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":190957,"source":{"system":"sec-edgar","filing":"0000899243-17-022826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924317022826/doc4.xml","form_type":"4"}},{"id":4250891,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-07-26T21:10:28.000Z","date":"2017-07-24","kind":"grant","acquired":true,"shares":90063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"shares","element":"transactionShares","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Reporting Person was initially granted an option to acquire 300,000 shares, 75,000 shares of which vested on May 25, 2016, and the remaining shares vested or vest in 36 substantially equal monthly installments starting on September 1, 2016, subject to the Reporting person's continued service with the Issuer and certain change of control provisions."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."}],"balance_after":90063,"derivative":{"exercise_price":0.45,"expiration_date":"2025-12-15","underlying":"Common Stock","underlying_shares":90063},"source":{"system":"sec-edgar","filing":"0000899243-17-019064","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924317019064/doc4.xml","form_type":"4"}},{"id":4250890,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2017-07-26T21:10:28.000Z","date":"2017-07-24","kind":"other","acquired":true,"shares":3803906,"ownership":{"direct":false,"nature":"Alpine Immunosciences, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alpine BioVentures GP, LLC is the general partner of Alpine Immunosciences, L.P. Dr. Venkatesan is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Venkatesan is also a limited partner of Alpine Immunosciences, L.P. By virtue of such relationships, Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by Alpine Immunosciences, L.P. and as a result may be deemed to have beneficial ownership of such shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3803906,"source":{"system":"sec-edgar","filing":"0000899243-17-019064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924317019064/doc4.xml","form_type":"4"}},{"id":4250889,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2017-07-26T21:10:28.000Z","date":"2017-07-24","kind":"grant","acquired":true,"shares":21739,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."}],"balance_after":21739,"source":{"system":"sec-edgar","filing":"0000899243-17-019064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924317019064/doc4.xml","form_type":"4"}},{"id":4250888,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2017-07-26T21:10:28.000Z","date":"2017-07-24","kind":"other","acquired":true,"shares":18633,"ownership":{"direct":false,"nature":"By Raj Venkatesan as UTMA custodian for Nathaniel Graham Venkatesan"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Raj Venkatesan as custodian for Reporting Person's sons under California Uniform Transfers to Minors Act."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":18633,"source":{"system":"sec-edgar","filing":"0000899243-17-019064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924317019064/doc4.xml","form_type":"4"}},{"id":4250887,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2017-07-26T21:10:28.000Z","date":"2017-07-24","kind":"other","acquired":true,"shares":18633,"ownership":{"direct":false,"nature":"By Raj Venkatesan as UTMA custodian for Reid Coleman Venkatesan"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Raj Venkatesan as custodian for Reporting Person's sons under California Uniform Transfers to Minors Act."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":18633,"source":{"system":"sec-edgar","filing":"0000899243-17-019064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413350/000089924317019064/doc4.xml","form_type":"4"}},{"id":4292802,"issuer":{"id":2090,"kind":"organization","name":"IOVANCE BIOTHERAPEUTICS, INC.","symbol":"IOVA"},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-05T21:25:38.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant. If the Reporting Person's service to the Issuer terminates before the expiration date, the option shares will be exercisable for two years following termination of service unless the Reporting Person is terminated for cause, in which case the options are terminated."}],"balance_after":35000,"derivative":{"exercise_price":5.45,"expiration_date":"2027-05-31","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001250853-17-000049","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425205/000125085317000049/primary_doc.xml","form_type":"4"}}]}